Vantia Therapeutics Pipeline

Vantia Therapeutics' pipeline draws on the Company's world-recognised expertise in small molecule drug development. Its drug discovery engine is based on the Ferring Research Ltd small molecule R&D unit, which was spun out from Ferring Pharmaceuticals in 2008. Focussed on first-in-class therapies for indications that are under-served by current products, Vantia Therapeutics' R&D group has over 20 years' experience in the development of small molecule modulators targeting hormones and proteases.

The Company owns an extensive drug candidate library, which is driving its clinical and preclinical portfolio, and intellectual property comprising 20 patent families and 21 granted patents.

The current status of Vantia Therapeutics' pipeline is shown below - click on a compound name, or click the links under the "Pipeline" menu on the left, for more information.

Platform	Compound	Indication(s)	MOA	Market Potential	Pre-Clinical	Phase 1	Phase 2	Phase 3	Year of NDA Target
GPCR	VA106483	Nocturia	V2 Agonist	$1bn					2012
GPCR	VA111913	Dysmenorrhoea	V1a Antagonist	$1-3bn					2013
Tissue Kallikrein	VA118020	Severe Asthma	KLK1 Inhibitor	$3-7bn					2014
Tissue Kallikrein	multiple	Inflammatory	KLK1 Inhibitor	TBA					TBA
Plasma Kallikrein	multiple	HAE/Diabetes	PKal Inhibitor	$1-2bn					2016
FAP Inhibitor	VA999260	Oncology/ Fibrosis	FAP Inhibitor	TBA					2016
FAP Inhibitor	multiple	Oncology/ Fibrosis	FAP Inhibitor	TBA					TBA